The "real-world" effectiveness and safety of omalizumab in patients with uncontrolled persistent allergic asthma in Slovakia: a subgroup analysis of the eXpeRience study.

Autor: Siracká S; Novartis Slovakia s.r.o., Bratislava, Slovakia., Tinková LD; Novartis Slovakia s.r.o., Bratislava, Slovakia., Hochmuth L; F.D. Roosevelt Hospital, Banská Bystrica, Slovakia., Leščišinová H; NsP Sv. Jakuba, Bardejov, Slovakia., Hrubiško M; Department of Clinical Immunology and Allergy, Oncology Institute of St. Elisabeth, Bratislava, Slovakia., Dostálová K; Outpatient Pulmonology Clinic Rockmed s.r.o., Bratislava, Slovakia., Jeseňák M; Department of Paediatrics, Department of Pulmonology and Phthisiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, University Teaching Hospital, Martin, Slovakia.

Publikováno v: Postepy dermatologii i alergologii [Postepy Dermatol Alergol] 2023 Feb; Vol. 40 (1), pp. 134-141. Date of Electronic Publication: 2022 Jun 01.